These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

103 related items for PubMed ID: 32962278

  • 1. Association between Polygenic Risk Score and One-Year Outcomes Following As-Needed Aflibercept Therapy for Exudative Age-Related Macular Degeneration.
    Shijo T, Sakurada Y, Yoneyama S, Kikushima W, Sugiyama A, Matsubara M, Fukuda Y, Mabuchi F, Kashiwagi K.
    Pharmaceuticals (Basel); 2020 Sep 20; 13(9):. PubMed ID: 32962278
    [Abstract] [Full Text] [Related]

  • 2. Genetic factors associated with response to as-needed aflibercept therapy for typical neovascular age-related macular degeneration and polypoidal choroidal vasculopathy.
    Yoneyama S, Sakurada Y, Kikushima W, Sugiyama A, Matsubara M, Fukuda Y, Tanabe N, Parikh R, Mabuchi F, Kashiwagi K, Iijima H.
    Sci Rep; 2020 Apr 28; 10(1):7188. PubMed ID: 32346038
    [Abstract] [Full Text] [Related]

  • 3. AREDS simplified severity scale as a predictive factor for response to aflibercept therapy for typical neovascular age-related macular degeneration.
    Sakurada Y, Kikushima W, Sugiyama A, Yoneyama S, Tanabe N, Matsubara M, Iijima H.
    Graefes Arch Clin Exp Ophthalmol; 2018 Jan 28; 256(1):99-104. PubMed ID: 29177890
    [Abstract] [Full Text] [Related]

  • 4. Association of CRP levels with ARMS2 and CFH variants in age-related macular degeneration.
    Shijo T, Sakurada Y, Fukuda Y, Yoneyama S, Sugiyama A, Matsubara M, Kikushima W, Tanabe N, Parikh R, Kashiwagi K.
    Int Ophthalmol; 2020 Oct 28; 40(10):2735-2742. PubMed ID: 32507953
    [Abstract] [Full Text] [Related]

  • 5. Incidence and risk factors of retreatment after three-monthly aflibercept therapy for exudative age-related macular degeneration.
    Kikushima W, Sakurada Y, Yoneyama S, Sugiyama A, Tanabe N, Kume A, Mabuchi F, Iijima H.
    Sci Rep; 2017 Mar 07; 7():44020. PubMed ID: 28266609
    [Abstract] [Full Text] [Related]

  • 6. Five-Year Outcome of Aflibercept Monotherapy for Exudative Age-Related Macular Degeneration with Good Baseline Visual Acuity.
    Kikushima W, Sakurada Y, Sugiyama A, Yoneyama S, Matsubara M, Fukuda Y, Kashiwagi K.
    J Clin Med; 2021 Mar 05; 10(5):. PubMed ID: 33807964
    [Abstract] [Full Text] [Related]

  • 7. Retreatment of Exudative Age-Related Macular Degeneration after Loading 3-Monthly Intravitreal Ranibizumab.
    Sugiyama A, Sakurada Y, Honda S, Miki A, Matsumiya W, Yoneyama S, Kikushima W, Iijima H.
    Ophthalmologica; 2018 Mar 05; 239(1):52-59. PubMed ID: 29045945
    [Abstract] [Full Text] [Related]

  • 8. [Age-related Macular Degeneration in the Japanese].
    Yoshimura N.
    Nippon Ganka Gakkai Zasshi; 2016 Mar 05; 120(3):163-88; discussion 189. PubMed ID: 27164756
    [Abstract] [Full Text] [Related]

  • 9. ARMS2 A69S polymorphism is associated with the number of ranibizumab injections needed for exudative age-related macular degeneration in a pro re nata regimen during 4 years of follow-up.
    Valverde-Megías A, Veganzones-de-Castro S, Donate-López J, Maestro-de-Las-Casas ML, Megías-Fresno A, García-Feijoo J.
    Graefes Arch Clin Exp Ophthalmol; 2017 Nov 05; 255(11):2091-2098. PubMed ID: 28744656
    [Abstract] [Full Text] [Related]

  • 10. Associations of the C2-CFB-RDBP-SKIV2L locus with age-related macular degeneration and polypoidal choroidal vasculopathy.
    Liu K, Chen LJ, Tam PO, Shi Y, Lai TY, Liu DT, Chiang SW, Yang M, Yang Z, Pang CP.
    Ophthalmology; 2013 Apr 05; 120(4):837-43. PubMed ID: 23260260
    [Abstract] [Full Text] [Related]

  • 11. Significance of C2/CFB variants in age-related macular degeneration and polypoidal choroidal vasculopathy in a Japanese population.
    Nakata I, Yamashiro K, Yamada R, Gotoh N, Nakanishi H, Hayashi H, Akagi-Kurashige Y, Tsujikawa A, Otani A, Saito M, Iida T, Oishi A, Matsuo K, Tajima K, Matsuda F, Yoshimura N.
    Invest Ophthalmol Vis Sci; 2012 Feb 16; 53(2):794-8. PubMed ID: 22232432
    [Abstract] [Full Text] [Related]

  • 12. Comparison of ARMS2/LOC387715 A69S and CFH Y402H risk effect in wet-type age-related macular degeneration: a meta-analysis.
    Jabbarpoor Bonyadi MH, Yaseri M, Nikkhah H, Bonyadi M, Nazari R, Soheilian M.
    Int Ophthalmol; 2019 Apr 16; 39(4):949-956. PubMed ID: 29423786
    [Abstract] [Full Text] [Related]

  • 13. Five-year outcomes of photodynamic therapy combined with intravitreal injection of ranibizumab or aflibercept for polypoidal choroidal vasculopathy.
    Wataru K, Sugiyama A, Yoneyama S, Matsubara M, Fukuda Y, Parikh R, Sakurada Y.
    PLoS One; 2020 Apr 16; 15(2):e0229231. PubMed ID: 32092094
    [Abstract] [Full Text] [Related]

  • 14. Association of ARMS2/LOC387715 A69S, CFH Y402H, and CFH I62V polymorphisms with retinal angiomatous proliferation compared with typical age-related macular degeneration: a meta-analysis.
    Jabbarpoor Bonyadi MH, Yaseri M, Bonyadi M, Soheilian M.
    Int Ophthalmol; 2017 Dec 16; 37(6):1397-1409. PubMed ID: 28005184
    [Abstract] [Full Text] [Related]

  • 15. Prognostic factors after aflibercept therapy for typical age-related macular degeneration and polypoidal choroidal vasculopathy.
    Ogasawara M, Koizumi H, Yamamoto A, Itagaki K, Saito M, Maruko I, Okada AA, Iida T, Sekiryu T.
    Jpn J Ophthalmol; 2018 Sep 16; 62(5):584-591. PubMed ID: 29974277
    [Abstract] [Full Text] [Related]

  • 16. Prospective clinical trial of Intravitreal aflibercept treatment for PolypoIdal choroidal vasculopathy with hemorrhage or exudation (EPIC study): 6 month results.
    Kokame GT, Lai JC, Wee R, Yanagihara R, Shantha JG, Ayabe J, Hirai K.
    BMC Ophthalmol; 2016 Jul 27; 16():127. PubMed ID: 27465105
    [Abstract] [Full Text] [Related]

  • 17. Age-related macular degeneration and coronary heart disease: evaluation of genetic and environmental associations.
    Keilhauer CN, Fritsche LG, Guthoff R, Haubitz I, Weber BH.
    Eur J Med Genet; 2013 Feb 27; 56(2):72-9. PubMed ID: 23103884
    [Abstract] [Full Text] [Related]

  • 18. Differentiation of exudative age-related macular degeneration and polypoidal choroidal vasculopathy in the ARMS2/HTRA1 locus.
    Liang XY, Lai TY, Liu DT, Fan AH, Chen LJ, Tam PO, Chiang SW, Ng TK, Lam DS, Pang CP.
    Invest Ophthalmol Vis Sci; 2012 May 31; 53(6):3175-82. PubMed ID: 22491416
    [Abstract] [Full Text] [Related]

  • 19. Efficacy of intravitreal aflibercept in Japanese patients with exudative age-related macular degeneration.
    Saito M, Kano M, Itagaki K, Sekiryu T.
    Jpn J Ophthalmol; 2017 Jan 31; 61(1):74-83. PubMed ID: 27660164
    [Abstract] [Full Text] [Related]

  • 20. Subfoveal Choroidal Thickness during Aflibercept Therapy for Neovascular Age-Related Macular Degeneration: Twelve-Month Results.
    Koizumi H, Kano M, Yamamoto A, Saito M, Maruko I, Sekiryu T, Okada AA, Iida T.
    Ophthalmology; 2016 Mar 31; 123(3):617-24. PubMed ID: 26686967
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.